Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Primmune Therapeutics logo — Engaging Innate Immunity to Cure Cancer

Primmune Therapeutics

Engaging Innate Immunity to Cure Cancer

Founded 2017 United States San Diego, United States 9 employees Series B Total: $56.90M Biotechnology, Health Care

General Information

Company Name Primmune Therapeutics
Founded Year 2017
Location United States San Diego, United States
Employees 9
Industries Biotechnology, Health Care
Funding Stage Series B
Business Model B2B
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Primmune Therapeutics. To contact Primmune Therapeutics, visit primmunerx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Primmune Therapeutics compare?

A PDF of Primmune Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Primmune Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Primmune Therapeutics

Primmune Therapeutics, founded in 2017, is a burgeoning player in the Biotechnology and Health Care industries, headquartered in the United States. Their slogan, "Engaging Innate Immunity to Cure Cancer," underscores their mission to enhance the efficacy of cancer treatments.

The company is pioneering the development of an orally administered TLR7 agonist. This novel approach aims to boost innate immunity, potentially revolutionizing the response rates to both existing and future cancer immunotherapy drugs.

With a recent $8.40M investment during their Series A round on 04 November 2021, Primmune Therapeutics is well-positioned for growth. However, the lack of disclosed investor names might prompt further inquiry into their funding network.

Their focus on innovative solutions in immunotherapy marks them as a significant entity within their field, inviting interest from potential investors keen on healthcare advancements.

Business keywords: Cancer Immunotherapy, TLR7 Agonist, Innate Immunity, Orally Administered, Medical Research, Patient Response, Immunotherapy Medicines, Cancer Treatment, Biopharmaceutical, Drug Development, Precision Medicine, Oncology, Clinical Trials, Therapeutic Innovation

Services & Products

Development of immune-activating cancer therapies
Clinical-stage biotechnology research
Advancement of oral small-molecule drug design
Conducting Phase 1 clinical trials

Target Customers

Oncologists Cancer patients Pharmaceutical industry partners Investors interested in biotech innovations

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $8.60M 3
Bioqube Ventures Oberland Capital Samsara BioCapital
Bioqube Ventures, Oberland Capital +1
01 Jan 2026
Series A $8.40M -
01 Nov 2021
Series A $4.00M 1
Bioqube Ventures
Bioqube Ventures
01 Jan 2021
Series A $27.40M 7
BioRock Ventures Polaris Partners BioBrit
BioRock Ventures, Polaris Partners +5
01 Oct 2020
Seed $7.00M 3
BioRock Ventures BioBrit CAM Capital
BioRock Ventures, BioBrit +1
01 Mar 2020
Seed $1.50M -
01 Jan 2018

Primmune Therapeutics Alternatives & Competitors

View All Alternatives
Primmune Therapeutics vs
Tallac Therapeutics
Tallac Therapeutics United States

Next generation immunotherapies for cancer patients: harnessing the power of innate and adaptive imm...

Debt Financing
18 employees
Biotechnology, Health Care
Primmune Therapeutics vs
MonTa Biosciences
MonTa Biosciences Denmark

Cancer Immunotherapy of Tomorrow

Venture round
11 employees
Biotechnology, Health Care
Primmune Therapeutics vs
Cascadian Therapeutics, Inc.
Cascadian Therapeutics, Inc. United States

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developin...

Post-IPO Equity
10 employees
Biotechnology, Health Care
View all alternatives

FAQ About Primmune Therapeutics

Engaging Innate Immunity to Cure Cancer
Primmune Therapeutics was founded in 2017.
Primmune Therapeutics is headquartered in San Diego, United States.
Primmune Therapeutics operates in Biotechnology and Health Care. Its work centres on Cancer Immunotherapy, TLR7 Agonist, Innate Immunity and Orally Administered. Its customers include Oncologists, Cancer patients and Pharmaceutical industry partners.
Primmune Therapeutics has a B2B business model. Its revenue comes from Licensing, Performance Based and Product Sales.
Primmune Therapeutics has approximately 9 employees.
Primmune Therapeutics has completed 6 funding rounds, raising a total of $56.90M. The latest funding stage is Series B.
Primmune Therapeutics offers: Development of immune-activating cancer therapies, Clinical-stage biotechnology research, Advancement of oral small-molecule drug design, Conducting Phase 1 clinical trials.
Top alternatives and competitors to Primmune Therapeutics include Tallac Therapeutics, MonTa Biosciences, Cascadian Therapeutics, Inc., ORIC Pharmaceuticals Inc., Inspirna, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Primmune Therapeutics and Tallac Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Primmune Therapeutics, https://bouncewatch.com/company/primmune-therapeutics, updated 21 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout